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Richard E KastAbstract
Based on reporting in the last several years, an impressive but dismal list of cytotoxic chemotherapies that fail to
prolong the median overall survival of patients with glioblastoma has prompted the development of treatment
protocols designed to interfere with growth-facilitating signaling systems by using non-cytotoxic, non-oncology
drugs. Recent recognition of the pro-mobility stimulus, interleukin-18, as a driver of centrifugal glioblastoma cell
migration allows potential treatment adjuncts with disulfiram and ritonavir. Disulfiram and ritonavir are well-tolerated,
non-cytotoxic, non-oncology chemotherapeutic drugs that are marketed for the treatment of alcoholism and human
immunodeficiency virus (HIV) infection, respectively. Both drugs exhibit an interleukin-18–inhibiting function. Given
the favorable tolerability profile of disulfiram and ritonavir, the unlikely drug-drug interaction with temozolomide,
and the poor prognosis of glioblastoma, trials of addition of disulfiram and ritonavir to current standard initial
treatment of glioblastoma would be warranted.
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After diagnosis, the median overall survival of patients
with glioblastoma is approximately 2 years [1]. The last
advance in treatment was the introduction of the Stupp
protocol in 2005, which involves maximal resection
followed by temozolomide and irradiation [1,2]. Recur-
rence occurs in almost all treated patients [1]. Over 40
trials of various traditional cytotoxic cancer chemothera-
peutic drugs reported in the last few years have failed to
significantly improve outcomes for patients with glio-
blastoma [3,4].
The current paper was, in part, prompted by a paper
by Yeh et al. [5] in 2012 that clearly noted the crucial
role of interleukin-18 (IL-18) in driving the centrifugal
migration of glioblastoma cells. Starting with a premise
that “the mediators and cellular effectors of inflamma-
tion are important (growth-enhancing) constituents of
the local environment of tumors,” Yeh et al. [5] showed
that non-malignant brain resident microglia secreted in-
creased active IL-18 when stimulated by a growingCorrespondence: richarderickast@gmail.com
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such triggering is via specific mediation of extracellular
matrix proteins, particularly fibronectin and vitronectin
synthesized and secreted by glioblastoma cells. This IL-
18–stimulated centrifugal migration is an important link
between glioblastoma pathology and treatment resist-
ance [5,6]. If such data in support of a feed-forward
cycle can be supported by further study, this would be a
perfect example of “cancer cells communicating actively”
with each other and with host cells and organs [7], giv-
ing us a tremendous insight into glioblastoma pathology
with immediate treatment consequences, which this
paper will delineate.Review
IL-18 in glioblastoma
In line with the observations by Yeh et al. [5], IL-18 has
been identified as an important growth- and motility-
driving element in many cancers (Figure 1). IL-18 is gen-
erally initially synthesized as a 24-kDa pro–IL-18 form,
later proteolytically maturing to its active 18-kDa form.
Both processes have been identified in a variety of can-
cers, such as gastric cancer [8], squamous cell carcinoman Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Feed-forward interleukin-18 (IL-18) cycle. Schematic
summary of the growth-enhancing feed-forward cycle reported by
Yeh et al. [5] shows that microglial-synthesized IL-18 (red triangles)
facilitates the migration of glioblastoma and that glioblastoma-
synthesized fibronectin (F) or vitronectin (V) stimulates microglial
IL-18 synthesis.
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[12], both primary and bone metastatic non–small cell
lung cancer [13], prostate cancer [14], small cell lung
cancer [15], hepatocellular carcinoma [16], metastatic
melanoma [17], and other human cancers.
Mammalian brain astrocytes and microglia express
both IL-18 and IL-18 receptors [18-22], forming an inte-
gral part of both normal glia-neuron dialogue and brain
tissue response to injury. Normal brain resident micro-
glia increase the synthesis of IL-18 under conditions of
infection, hypoxic-ischemic, and traumatic brain injuries,
for example [23,24]. IL-18 is an important link in the de-
velopment of both normal protective and pathological
inflammation [25,26], among many other pathways, by
promotion of interferon gamma synthesis and furthering
Th1 helper T-cell development [27]. IL-18 is a core me-
diator of angiogenesis and inflammation in rheumatoid
arthritis pannus formation [28].
Proteolytic maturation is mediated by IL-1beta–convert-
ing enzyme (ICE), synonymous with caspase-1. Caspase-1
is a 60-kDa multimeric protease composed of two 20-kDa
and two 10-kDa subunits. Caspase-1 itself is translated
initially into a 45-kDa pro-caspase-1, appearing on the
outer cell membrane [29,30].
IL-18 and cellular migration
Triggering migration is among the more prominent effects
of exposing cells to IL-18. The migratory capacity ofnormal cardiac fibroblasts [31,32], normal macrophages
[33], vessel wall transmigrating neutrophils [34], and
coronary artery smooth muscle cells [35] increases in
response to IL-18 exposure. Migration rate of normal
human skin melanocytes increases after IL-18 exposure
[36], as does that of dermal Langerhans cells [37] and
murine melanoma cells [38,39].
IL-18–mediated increase in centrifugal migration was
observed in gastric cancer cells [8,40] similar to what Yeh
et al. [5] found in glioblastoma. Increased circulating IL-
18 was observed in patients with gastric cancer [41], head
and neck squamous cell carcinoma [10], esophageal can-
cer [41], epithelial ovarian cancer [42], and non–small cell
lung cancer [15,43] where higher levels of IL-18 were as-
sociated with poorer overall survival [13], in patients with
breast cancer [44] where levels of IL-18 in metastatic dis-
ease were also higher than those in non-metastatic disease
[45], and in patients with prostate cancer [14], small cell
lung cancer [15], and pancreatic cancer where higher
levels of IL-18 predicted poorer overall survival [46]. The
common theme in these studies is that IL-18 increases
most with metastatic disease. These findings, combined
with IL-18–stimulated centrifugal migration in gastric
cancer cells [8,40] and glioblastoma cells [5], point to
IL-18 as a general mobility-enhancing signaling mol-
ecule for cancers.
A dramatic and instructive finding in this regard was
reported by Jiang et al. [47] in 2003. In studying two
subclones of the same human lung cancer cell line, one
highly metastatic and the other poorly so, the authors
concluded that robust IL-18 synthesis by the metastatic
subclone was the determining factor in the different sub-
clones’ behaviors, namely higher motility and metastatic
competence in the higher IL-18–producing subclone.
Disulfiram and ritonavir
Disulfiram is a 297-Da aldehyde dehydrogenase inhibitor
used clinically since the 1950s to treat alcoholism, and it
is still widely used worldwide [48]. Ritonavir is a 721-Da
antiviral drug, one of the first-generation protease inhibitors
marketed in the 1980s to treat human immunodeficiency
virus (HIV) infection [49].
Disulfiram and ritonavir form 2 of the 9-drug regimen
to augment temozolomide in the coordinated undermin-
ing of survival paths 9 (CUSP9*) treatment protocol for
recurrent glioblastoma. The rationale for these drugs
was provided in the CUSP9 and CUSP9* papers [3,4],
but it did not include considerations of the effects of
disulfiram or ritonavir on IL-18. Detailed pharmacologic
analysis in the CUSP9 papers indicated the unlikelihood
of drug-drug interaction between either disulfiram or ri-
tonavir or both and temozolomide [3,4]. What not dis-
cussed in these papers but reviewed here are additional
data indicating that disulfiram and ritonavir can limit
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during primary Stupp protocol treatment.
The data showing the function of IL-18 in inhibiting
the actions of disulfiram and ritonavir were previously
reviewed in connection with their potential to mitigate
inflammation associated with acute pancreatitis [50] or
central nervous system (CNS) inflammation after blast
exposure [51]. A study reported in 1997 showed potent
caspase-1 inhibition by disulfiram [52], which would
block pro–IL-18 maturation. Ritonavir decreases caspase-
1 expression [53-55].
We have convincing evidence that both ritonavir and
disulfiram or their active metabolites penetrate the blood–
brain barrier effectively in sufficient concentrations [56-60].
The most common clinical use of disulfiram is to inhibit
aldehyde dehydrogenase during the treatment of alcohol-
ism [48]. A secondary use of disulfiram is to inhibit brain
dopamine beta-hydroxylase during the treatment of cer-
tain addictions [56,57], thus indicating sufficient blood–
brain penetration. The levels of ritonavir in the brain tis-
sues and cerebrospinal fluid (CSF) tend to be low [58]
when given orally, but can easily be increased from 2.4 to
6.6 ng/mL CSF with oral co-administration of ketocona-
zole [59]. We believe that these levels are sufficient based
on in vitro studies and observations of CSF clearance of
HIV with oral ritonavir [60].
Additional IL-18 considerations
Exogenous IL-18 is being investigated in several active
research programs for its ability to stimulate immune re-
sponses to glioma cells [61-63]. Data indicating that IL-
18 can enhance an anti-tumor immune response as well
as being a trophic factor for many cancers were reviewed
in 2007 by Park et al. [64]. Which factors predominate
during human cancer progression remains unclear today.
Given 1) the findings of Yeh et al. [5], which are con-
cordant with a wealth of data on the active role of IL-18
in the dissemination of other cancers, and 2) the widely
dispersed microsatellites within the brain tissues that
go on to be fatal in glioblastoma, the safest supposition
for now is that the net effect of IL-18 in glioblastoma is
negative.
Thus, there is potential for the suggested combination
of disulfiram and ritonavir to reduce an immune re-
sponse to glioblastoma cells, but if the preponderant ef-
fect of IL-18 is to stimulate centrifugal migration, the
net effect may well be clinically beneficial. Given the the-
oretical immunostimulatory aspect of IL-18 function,
the paradox of finding increased circulating IL-18 as a
negative prognostic portent has been discussed without
resolution in the context of both pancreatic cancer [65]
and breast cancer [66].
The 9-drug regimen CUSP9* designed for recurrent
glioblastoma after Stupp protocol treatment [3] alreadyincludes both disulfiram and ritonavir for reasons that
do not include IL-18 inhibition. Given the likely centri-
fugal migration driven by IL-18 and unlikely additional
adverse effect burden of adding concurrent disulfiram
and ritonavir, we have the potential to improve initial
treatment with the Stupp protocol [1,2], temozolomide,
and irradiation after maximal surgical resection.
In vitro irradiation of microglia increases their IL-18
synthesis [67]. In vivo brain irradiation up-regulates
microglial IL-18 synthesis in situ and increases the
number of IL-18–producing microglia [68]. Of particu-
lar note, irradiation-induced increased microglial IL-18
is not transient and may indeed be permanent [68]. In-
deed, low-dose, whole body irradiation dose propor-
tionately increases circulating IL-18 in mice, pigs, and
non-human primates [69]. Thus, as part of the stand-
ard Stupp protocol for initial treatment of glioblast-
oma, in addition to killing much of the primary tumor
mass and consequently somewhat lengthening overall
survival, irradiation can be expected to stimulate IL-
18–driven centrifugal migration of the few surviving
glioblastoma cells. Stimulating the centrifugal migra-
tion of glioblastoma cells leads to their wide dissemin-
ation and sets up conditions for later fatal recurrence,
the classic double-edged sword. Disulfiram and ritona-
vir may have potential to overcome the pathophysi-
ology of glioblastoma and improve the results of the
Stupp protocol as currently constituted.
Conclusions
We have demonstrated how a feed-forward, IL-18–based,
growth-enhancing system forms an element of glioblast-
oma pathophysiology whereby glioblastoma cells secrete
extracellular matrix proteins, such as fibronectin and
vitronectin, and these proteins then stimulate surrounding
normal brain microglia to secrete increased IL-18 [5]. The
accumulation of IL-18 stimulates centrifugal glioblastoma
cell migration and then stimulates a new set of microglia
at the growing front to synthesize IL-18. These centri-
fugally migrating cells ultimately prove to be untreat-
able and fatal.
Two old, well-tolerated, low-risk drugs, disulfiram and
ritonavir, have been shown to interfere with IL-18 gener-
ation/function, but with little evidence that they would
increase the burden of adverse effects or interfere with
Stupp protocol interventions, temozolomide, and radi-
ation. Therefore, the risk-benefit ratio favors adding con-
comitant disulfiram and ritonavir to the standard Stupp
protocol.
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